Big Pharma Companies Open Up Cancer Trial Comparator Arm Data
A lot has changed in clinical trial transparency since Project Data Sphere outlined plans to share cancer results in 2012, with the European law voted in last week then still a distant threat. Even so, Pfizer ($PFE), Sanofi ($SNY) and the other groups behind the initiative think it still offers something different now that it has belatedly launched.
Pfizer and Sanofi have joined with AstraZeneca ($AZN), Bayer, Celgene ($CELG), Johnson & Johnson ($JNJ) and Memorial Sloan-Kettering Cancer Center to set up Project Data Sphere. Together, the groups have contributed comparator-arm data from 9 clinical trials, with results from more studies and organizations to follow soon. Focusing on comparator-arm data made it easier to get companies to join the initiative because fears about giving away proprietary information are reduced.
The decision also limits the usefulness of the database--it isn't the trove of data on marketed drugs that transparency campaigners want--but it can nonetheless play a role in improving development. "Understanding the expected outcome for a comparator arm is a very important step in designing new clinical trials. It will help with physical assumptions, the sizing of a trial, and other design logistics," Pfizer's oncology medical affairs lead, Ronit Simantov, told PharmExec.
- Tags:
- AstraZeneca (AZ)
- Bayer
- Big Pharma
- cancer
- Celgene (CELG)
- Charles Hugh-Jones
- clinical trial transparency
- comparator-arm data
- Johnson & Johnson (JNJ)
- Memorial Sloan-Kettering Cancer Center (MSKCC)
- oncology
- open research
- Pfizer (PFE)
- PharmExec
- Project Data Sphere
- prostate cancer
- Ronit Simantov
- Sanofi (SNY)
- Login to post comments